Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies

Clinical Cancer Research

Volumn 17, Issue 24, 2011, Pages 7765-7775

  Fishman, Mayer N ^a   Thompson, John A ^b   Pennock, Gregory K ^c   Gonzalez, Rene ^d   Diez, Luz M ^a   Daud, Adil I ^a,f   Weber, Jeffery S ^a   Huang, Bee Y ^e   Tang, Shamay ^e   Rhode, Peter R ^e   Wong, Hing C ^e  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c M D ANDERSON CANCER CENTER ORLANDO   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^e ALTOR BIOSCIENCE CORPORATION   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; BILIRUBIN; CISPLATIN; DACARBAZINE; DOCETAXEL; DOPAMINE; GAMMA INTERFERON; HLA A ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 2; PI 88; PROTEIN ALT 801; PROTEIN P53; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CONTROL; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CHILL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; GAMMA INTERFERON BLOOD LEVEL; HEAD AND NECK CANCER; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUROENDOCRINE TUMOR; PAIN; PATIENT CARE PLANNING; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PRURITUS; PULMONARY PAIN; RADIODIAGNOSIS; SIDE EFFECT; SINUS TACHYCARDIA; SUPRAVENTRICULAR TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR ALPHA BLOOD LEVEL; URINE VOLUME;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPITOPES; FEMALE; FEVER; HLA-A2 ANTIGEN; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON-GAMMA; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84055212017     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1817     Document Type: Article

References (19)

1. Fishman MN, Pennock GK, Diez LM, Edwards J, Tang S, Huang BY, et al. Immune pharmacodynamics of TCR-IL2 fusion protein ALT-801 on cytokines and lymphocytes in initial human experience [abstract 8082]. Translational Cancer Medicine 2008: Bridging the Lab and the Clinic in Cancer Medicine. 2008 Nov; Jerusalem, Israel.
2. Fishman MN, Pennock GK, Tang S, Huang BY, Chavaillaz PA, Egan JO, et al. Interim analysis of a phase I clinical trial of TCR-IL2 fusion protein ALT-801 in patients with metastatic malignancies [abstract]. Cancer Immunology and Immunotherapy: Realizing the Promise. 2008 Sep; Bethesda, MD.
3. Pennock GK, Fishman MN, Gonzalez R, Thompson J, Huang BY, Tang S, et al. Phase I clinical experience of a targeted TCR-IL2 fusion protein in patients with metastatic malignancies. J Clin Oncol 2009;27:abstr. 3040.
4. Fishman MN, Pennock GK, Gonzalez R, Thompson JA, Huang BY, Tang S, et al. Phase I clinical experience of a targeted TCR-IL2 fusion protein in patients with metastatic malignancies. Keystone Symposia on Molecular and Cellular Biology: Target Cancer Therapies. 2009 Mar; Whistler (BC), Canada.
5. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-84; discussion 484-5.
6. Card KF, Price-Schiavi SA, Liu B, Thomson E, Nieves E, Belmont H, et al. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Cancer Immunol Immunother 2004;53:345-57. (Pubitemid 38392312)
7. Wen J, Zhu X, Liu B, You L, Kong L, Lee HI, et al. Targeting activity of a TCR/IL-2 fusion protein against established tumors. Cancer Immunol Immunother 2008;57:1781-94.
8. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6. (Pubitemid 21896613)
9. Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell 2005;120:7-10. (Pubitemid 40094596)
10. Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, Appella E, et al. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: Implications for immunoselection of epitope loss variants. J Immunol 2000;165:5938-44.
11. Zhu X, Belmont HJ, Price-Schiavi S, Liu B, Lee HI, Fernandez M, et al. Visualization of p53 (264-272)/HLA-A*0201 complexes naturally presented on tumor cell surface by a multimeric soluble single-chain T cell receptor. J Immunol 2006;176:3223-32.
12. Belmont HJ, Price-Schiavi S, Liu B, Card KF, Lee HI, Han KP, et al. Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein. Clin Immunol 2006;121:29-39. (Pubitemid 44380410)
13. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993;11:245-68.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
15. Konrad MW, Hemstreet G, Hersh EM, Mansell PW, Mertelsmann R, Kolitz JE, et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res 1990;50:2009-17. (Pubitemid 20115067)
16. Atkins MB, Redman B, Mier J, Gollob J, Weber J, Sosman J, et al. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Clin Cancer Res 2001;7:486-92. (Pubitemid 32707969)
17. Mier JW, Vachino G, Klempner MS, Aronson FR, Noring R, Smith S, et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 1990;76:1933-40.
18. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16. (Pubitemid 29318842)
19. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.